News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

EPICS-III shows saroglitazar potential for select PBC patients
08 Jun 2026
byAudrey Abella
In the phase IIb/III EPICS-III study, the dual PPAR-α/γ agonist saroglitazar improves biochemical response (BCR) rates among individuals with primary biliary cholangitis (PBC) who had an inadequate response or intolerance to ursodeoxycholic acid (UDCA).








